Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers

被引:43
作者
Bruhwyler, Jacques [3 ]
Carreer, Fabienne [3 ]
Demanet, Etienne [2 ]
Jacobs, Heidi [1 ]
机构
[1] Cosucra Grp Warcoing Sa, B-7740 Warcoing, Belgium
[2] ResearchLink Sprl, Thuin, Belgium
[3] Squarepoint Pointcarre Sprl, Ecaussinnes, Belgium
关键词
Inulin; fructan; tolerance; gastro-intestinal; healthy volunteers; HUMAN COLONIC MICROBIOTA; FECAL BIFIDOBACTERIA; DIETARY MODULATION; CHICORY INULIN; OLIGOFRUCTOSE; OLIGOSACCHARIDES; GLUCOSE; FIBER;
D O I
10.1080/09637480701625697
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Background Similar to other indigestible carbohydrates or dietary fibres, a consumption of too large quantities of inulin-type fructans may cause some digestive problems. Aim To compare the digestive tolerance of inulin-type fructans, administered during 2 weeks, at different doses. Methods Eighty-four healthy volunteers (aged 18-45 years, mean body mass index 25.1 kg/m2 and mean total fibre consumption 12 g) were included in a double-blind, placebo-controlled, randomized, cross-over study comparing Fibrulose F97 (5 and 20 g/day), Fibruline Instant (5, 10 and 20 g/day) and Fibruline XL (10 g/day) (degrees of polymerization respectively equal to 2-20, 2-60 with an average of 10, and 2-60 with an average 20) to placebo. The study was decomposed into five 2-week periods: placebo run-in, treatment 1, placebo washout, treatment 2, placebo run-out. The following symptoms were assessed using visual analogue scales: flatulence, rumbling, bloating, abdominal pain, abdominal cramps, nausea, stool frequency and stool consistency. The primary variable was the mean difference between treatment and placebo in terms of tolerance (sum of the eight visual analogue scales). Results The three products tended to increase digestive symptoms whatever the dose but the change was mild (maximum, +19 mm on the 800-mm scale) and significant (P0.001) for Fibruline Instant at 20 g/day only. At 20 g/day, a statistically significant difference between Fibruline Instant and Fibrulose F97 was demonstrated (P=0.011). There was a dose-effect relationship both for Fibrulose F97 (P0.05) and Fibruline Instant (P=0.042). All the other tendencies were non-significant. Conclusions The three different inulin-type fructans were very well tolerated.
引用
收藏
页码:165 / 175
页数:11
相关论文
共 50 条
  • [31] Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
    Kudiganti, Venkateshwarlu
    Kodur, Raveendra Ramamurthy
    Kodur, Sushma Raveendra
    Halemane, Manjunath
    Deep, Dheeraj Kumar
    LIPIDS IN HEALTH AND DISEASE, 2016, 15
  • [32] Effect of arabinogalactan on the gut microbiome: A randomized, double-blind, placebo-controlled, crossover trial in healthy adults
    Chen, Oliver
    Sudakaran, Sailendharan
    Blonquist, Traci
    Mah, Eunice
    Durkee, Shane
    Bellamine, Aouatef
    NUTRITION, 2021, 90
  • [33] Effects of carbohydrates-BCAAs-caffeine ingestion on performance and neuromuscular function during a 2-h treadmill run: a randomized, double-blind, cross-over placebo-controlled study
    Peltier, Sebastien L.
    Vincent, Lucile
    Millet, Guillaume Y.
    Sirvent, Pascal
    Morin, Jean-Benoit
    Guerraz, Michel
    Geyssant, Andre
    Lescuyer, Jean-Francois
    Feasson, Leonard
    Messonnier, Laurent
    JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION, 2011, 8
  • [34] Impact of β2-1 fructan on faecal community change: results from a placebo-controlled, randomised, double-blinded, cross-over study in healthy adults
    Clarke, Sandra T.
    Brooks, Stephen P. J.
    Inglis, G. Douglas
    Yanke, L. Jay
    Green, Judy
    Petronella, Nicholas
    Ramdath, D. Dan
    Bercik, Premysl
    Green-Johnson, Julia M.
    Kalmokoff, Martin
    BRITISH JOURNAL OF NUTRITION, 2017, 118 (06) : 441 - 453
  • [35] Effect of Continuous Ingestion of Bifidobacteria and Inulin on Reducing Body Fat: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study
    Baba, Yuhei
    Saito, Yasuo
    Kadowaki, Mei
    Azuma, Naoki
    Tsuge, Daisuke
    Guerra, Nelson P.
    NUTRIENTS, 2023, 15 (24)
  • [36] Milk Powder Co-Supplemented with Inulin and Resistant Dextrin Improves Glycemic Control and Insulin Resistance in Elderly Type 2 Diabetes Mellitus: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Cai, Xiaxia
    Yu, Huanling
    Liu, Lan
    Lu, Tong
    Li, Jingjie
    Ji, Yacheng
    Le, Zhiyin
    Bao, Lei
    Ma, Weiwei
    Xiao, Rong
    Yang, Yuexin
    MOLECULAR NUTRITION & FOOD RESEARCH, 2018, 62 (24)
  • [37] Pantoprazole Improves Glycemic Control in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Singh, Pawan Kumar
    Hota, Debasish
    Dutta, Pinaki
    Sachdeva, Naresh
    Chakrabarti, Amitava
    Srinivasan, Anand
    Singh, Inderjeet
    Bhansali, Anil
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (11) : E2105 - E2108
  • [38] Effect of two dietary fibers on satiety and glycemic parameters: a randomized, double-blind, placebo-controlled, exploratory study
    Savastano, David M.
    Hodge, Rebecca J.
    Nunez, Derek J.
    Walker, Ann
    Kapikian, Roxanne
    NUTRITION JOURNAL, 2014, 13
  • [39] Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study
    Garcia-Gea, Consuelo
    Rosa Ballester, Maria
    Martinez, Juan
    Maria Antonijoan, Rosa
    Donado, Esther
    Izquierdo, Inaki
    Barbanoj, Manuel-Jose
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (06) : 663 - 674
  • [40] Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study
    Remenyi, Akos
    Grosz, Andor
    Szabo, Sandor Andras
    Totka, Zsolt
    Molnar, David
    Helfferich, Frigyes
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (09) : 859 - 868